EU IVDR Transition Conditions under Article 110
Updated: 2026-11-12 · GRZAN Regulatory Team · Verification date 2026-10-20
1. Key takeaways
Continuing to benefit from the transition period under Article 110 requires two sets of conditions to be met simultaneously. The continuous conditions are: continued conformity with the original directive, no significant changes in design or intended purpose, and no unacceptable risk to health and safety. The time-point conditions are: establishing an IVDR quality management system conforming to Article 10(8) (before 26 May 2025), submitting the application for IVDR certification to a notified body (Class D 26 May 2025, Class C 26 May 2026, Class B and Class A sterile 26 May 2027), and signing a written agreement (Class D 26 September 2025, Class C 26 September 2026, Class B and Class A sterile 26 September 2027).
Missing any single time point ends the transitional period for the affected products, and failing a continuous condition ends it at the moment of failure. Because the QMS deadline applies uniformly to all classes, it is both the earliest and the most easily underestimated obligation in the entire legacy portfolio.
2. Legal basis
The table below lists the sources for the transition conditions and their time points.
| Regulation / document | Provision | Date | Source |
|---|---|---|---|
| Regulation (EU) 2017/746 (IVDR) | Article 110 (transition provisions, as amended); Article 10(8) (quality management system) | Adopted 2017-04-05; applies from 2022-05-26 | EUR-Lex |
| Regulation (EU) 2024/1860 | Amends Article 110, setting the QMS, application and written-agreement time points | Adopted 2024-06-13; entered into force 2024-07-09 | EUR-Lex |
| HPRA (Ireland) official page | Table of transition conditions and time points (QMS 2025-05-26; applications 2025, 2026, 2027-05-26; written agreements 2025, 2026, 2027-09-26) | Version current in 2026 | Member State competent authority website |
| European Commission official question-and-answer document on the MDR/IVDR extensions | Interpretation of the conditions and their application | 2024 | European Commission |
Where the amending regulation and national authority tabulations differ in presentation, the binding text remains the consolidated Article 110 as amended by Regulation (EU) 2024/1860; the national pages serve as practical checklists.
3. Expert insights
Insight 1: the QMS time point is the single uniform deadline, and it has already passed.
According to the condition tables published by competent authorities, the time point for establishing a quality management system conforming to Article 10(8) of the IVDR is 26 May 2025, and it is not segmented by class. The Commission’s question-and-answer document adds that devices which were self-declared under the IVDD, and never certified by a notified body, must also have an IVDR-compliant QMS in place from 26 May 2025 if the transition is to be enjoyed; where none is established, the transitional period ends on that date. This is currently the largest stock of residual compliance risk, because the self-declared segment of the market has the least experience with notified body-grade quality systems.
Insight 2: the application submission and the written agreement are two independent time points, about four months apart.
The two time points are staggered by class: Class D at 26 May 2025 and 26 September 2025, Class C at 26 May 2026 and 26 September 2026, and Class B and Class A sterile at 26 May 2027 and 26 September 2027. Submitting the application without signing a written agreement within the window also fails the conditions. Since notified body capacity is scheduled contractually, the four-month gap is a hard constraint on negotiation timelines, not a formality, and it should be built into every quotation and audit planning discussion.
Insight 3: not applying is also permitted, but the consequences are explicit.
The Commission’s document makes clear that manufacturers are under no obligation to apply for IVDR certification for their legacy devices. Where a certificate expires after 9 July 2024 and before 26 May 2025, an extension can still be enjoyed if the conditions are met; but where the manufacturer does not submit an application for conformity assessment, the transitional period ends at the application time point. Each product line should therefore receive an explicit decision, apply or withdraw, documented at management level, rather than drifting into an accidental lapse through inaction.
Insight 4: the scope of the QMS must align with the thirteen aspects of Article 10(8).
Article 10(8) lists the aspects a QMS must at least cover: (a) regulatory compliance strategy and change management; (b) identification of and response plans for applicable GSPRs; (c) management responsibility; (d) resource management; (e) risk management; (f) performance evaluation including PMPF; (g) product realisation; (h) UDI assignment and verification; (i) the post-market surveillance system; (j) communication; (k) vigilance reporting; (l) corrective and preventive actions; and (m) monitoring and measurement of outputs and data analysis. Treating an ISO 13485 certificate as sufficient evidence of the QMS usually falls short, because the mapping from the standard onto these thirteen aspects must be demonstrated, not presumed.
4. Practical recommendations
- Start with a QMS gap analysis: use the thirteen items of Article 10(8) as the checklist and close each item with procedures and records.
- Draw a dual-node Gantt chart of application submission and written agreement per class, and treat notified body scheduling as a predecessor dependency.
- Run an entry-by-entry impact analysis for partial-application scenarios, so that uncovered entries do not lapse early.
- Assemble an evidence package: records of QMS establishment, submission receipts, the original written agreement and copies of certificates.
- For product lines that are being withdrawn, start early on the Article 10a supply-interruption notification assessment and customer communication (see part 45 of this series).
5. Verification checklist
- □ A QMS conforming to Article 10(8) established, with evidence of effectiveness before 26 May 2025 retained
- □ IVDR certification applications submitted by class before 2025, 2026 or 2027-05-26
- □ Written agreements signed by class before 2025, 2026 or 2027-09-26
- □ Entry-by-entry impact analysis completed for the partial-application scenario
- □ The continuous conditions, conformity, no significant changes, no unacceptable risk, integrated into internal audits
- □ The evidence package archived and available to competent authorities on request
Regulatory information verified as of 29 October 2026.
GRZAN manages transition-condition compliance under Article 110, from QMS gap analyses against Article 10(8) to the sequencing of applications and written agreements with notified bodies, keeping legacy IVD portfolios eligible through to IVDR certification. For tailored compliance support on the EU IVDR market, contact info@grzanglobal.com.
Disclaimer
Prepared by GRZAN from publicly available regulation. It is provided for general information only and does not constitute legal advice. Legislation and official fees are subject to change by the competent authority.
About GRZAN
GRZAN (Global Regulatory Zone Access Navigator) — the global market-access navigator for medical devices and IVDs.
GRZAN is a specialist consultancy for medical device and IVD market access, providing end-to-end regulatory solutions across the product lifecycle and making international market entry simpler and faster.
Key figures. More than 25 wholly owned subsidiaries worldwide covering 50+ countries and regions; chosen by 100+ listed and leading Chinese device manufacturers, with 4,000+ successful cases; 12+ years in the sector and 200+ regulatory training sessions and seminars delivered.
What we do. Global market access: multi-country registration programmes, technical documentation, regulatory advice. Clinical evidence: clinical evaluation reports (CER), usability studies, overseas clinical investigations. Quality systems: ISO 13485, MDSAP, FDA QMSR and BGMP implementation and audit readiness. Authorised representative and licence-holder services across Southeast Asia, Latin America, the Middle East, Africa, Europe and North America.
Why GRZAN. A real operating entity, with the certificate held by the manufacturer: our direct overseas subsidiaries act as the compliant local holder, so the regulatory relationship stays clear and you keep control rather than being tied to a distributor. Direct access to the team: no time-zone gap, no language barrier, no cultural gap. Review points anticipated: we know what FDA 510(k), EU MDR, Southeast Asian, Latin American and Middle Eastern reviewers look for, which shortens timelines and reduces deficiency letters. Pathway planning: pre-decision analysis and risk assessment before you commit.
Every engagement rests on three commitments: efficiency through pre-submission review, certainty through a clear pathway, and stability through a licence-holder that stays in place.
Take your devices global with GRZAN
We work with manufacturers worldwide to open new markets with a clear regulatory pathway.
Contact us